Chronic Anal Fissure (>8 Weeks)
Investigational adjunct for chronic anal fissure refractory to medical therapy; very limited case-report evidence; surgical sphincterotomy remains gold standard.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for anal fissures. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for chronic anal fissures is investigational and considered high-infection-risk.
- ¿Qué evidencia existe?
- Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based therapy for chronic anal fissures per ASCRS guidelines: fiber supplementation and sitz baths, topical nitroglycerin 0.2-0.4% or topical nifedipine, botulinum toxin injection, and lateral internal sphincterotomy (gold standard for refractory disease, >90 percent cure). The perianal area is high-risk for bacterial superinfection of any breach in the skin barrier.
- Riesgos principales
- Severe infection risk from leech placement in the perianal area (fecal flora)
- Bleeding from bite sites that may obscure fissure-related bleeding
- Local skin infection or, rarely, Aeromonas infection in a contaminated area
- Worsening of fissure pain from procedure-related trauma
- Anal abscess or fistula formation
- Allergic reaction to leech saliva (uncommon)
- Delay of evidence-based topical nitroglycerin, nifedipine, botulinum toxin, or sphincterotomy
- Risk of missed underlying inflammatory bowel disease or anorectal malignancy
- Quién no debería considerar esto
- Patients with active perianal infection, abscess, or fistula
- Patients with inflammatory bowel disease (Crohn perianal disease)
- Patients with suspected anorectal malignancy
- Patients with HIV or immunocompromise (severe infection risk)
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients who have not tried topical nitroglycerin or nifedipine
- Patients who have not been evaluated by a colorectal surgeon
- Qué preguntar a su clínico
- Has inflammatory bowel disease or anorectal malignancy been ruled out?
- Have I tried fiber supplementation, sitz baths, and topical nitroglycerin or nifedipine?
- Am I a candidate for botulinum toxin injection or lateral internal sphincterotomy (>90 percent cure)?
- What is the realistic infection risk from leech placement in the perianal area?
- What evidence specifically supports leech therapy for anal fissures?
- What is the practitioner's antibiotic and infection-control protocol?
- What is the cost and is it covered by insurance? (typically not covered)
- Cuándo buscar atención urgente
- Severe perianal pain with fever (possible anal abscess — surgical emergency)
- Persistent rectal bleeding, mucus, or pus
- New incontinence or inability to control bowel movements
- Spreading redness, warmth, pus, or red streaks (cellulitis or abscess)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
Qué NO significa esto
- This is NOT FDA-cleared for anal fissures.
- Anecdotal reports do NOT establish efficacy versus topical nitroglycerin, nifedipine, botulinum toxin, or lateral internal sphincterotomy.
- It does NOT substitute for evidence-based pharmacologic or surgical therapy.
- It does NOT mean perianal leech application is safe — fecal flora and abscess risk are real.
- It does NOT replace colorectal surgical evaluation when standard therapy fails.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- gastrointestinal
- ICD-10
- K60.1
- Safety tier
- medium
Evidence Summary
Chronic anal fissure (>8 weeks) is conventionally treated with topical glyceryl trinitrate or diltiazem (roughly 50-60% healing), botulinum toxin injection (roughly 60-70% healing), and lateral internal sphincterotomy (the gold standard, >90% healing but with about a 10% risk of minor incontinence). No PubMed-indexed controlled trial or case report of leech therapy for anal fissure has been published; use for this indication is investigational and mechanistic only. Sphincter manometry and proctologic evaluation are appropriate before considering any complementary therapy, and IBD-related fissures require gastroenterology management.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Patel N et al. (2022)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Posterior or lateral atypical fissure (workup for IBD, malignancy)
- Active perianal abscess or fistula
- Crohn's disease perianal manifestation
- Prior anal sphincter surgery with incontinence
Related Conditions
Hemorrhoids (Grade II-III, Symptomatic)
Investigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.
External Thrombosed Hemorrhoid (Acute, <72h)
Investigational adjunct for acute external thrombosed hemorrhoids presenting within 72 hours; distinct from internal hemorrhoidal disease.
Non-Alcoholic Fatty Liver Disease (Investigational Adjunct)
Investigational adjunct in NAFLD/MASLD; small case series only; weight loss, dietary modification, and resmetirom remain primary.
Hepatic Portal Congestion (Non-Cirrhotic, Investigational)
Highly investigational adjunct for non-cirrhotic hepatic congestion; case reports only; cirrhosis and portal hypertension are absolute exclusions.